Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacopan vs Glucocorticoids in ANCA-associated Vasculitis (ARRIA)
NCT06611696Phase 4Recruiting
- Sponsor
- Chiba University
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 arms), sponsored by Chiba University. Primary endpoint: Proportions of patients achieving remission at 26 weeks. Started Nov 2024; status: recruiting.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06611696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611696.